enVVeno Medical Corp
Change company Symbol lookup
Select an option...
NVNO enVVeno Medical Corp
MTBC CareCloud Inc
WRK Westrock Co
SNDX Syndax Pharmaceuticals Inc
SLAMU Slam Corp
SURYY Sumitomo Realty & Development Co Ltd
DAC Danaos Corp
MGU Macquarie Global Infrastructure Total Return Fund Inc.

Health Care : Health Care Equipment & Supplies | Small Cap Growth
Company profile

enVVeno Medical Corporation is a med-tech company. The Company is focused on improving the standard of care in the treatment of venous disease. The Company is focused on developing tissue-based solutions that are designed for patients with chronic venous insufficiency (CVI). Its lead product, VenoValve, is a porcine based device being developed to surgically implanted in the deep venous system of the leg to treat severe CVI, including the potential to heal recurring venous leg ulcers. The VenoValve is designed to be implanted into the femoral vein of the patient in an open surgical procedure via a five-to-six-inch incision in the upper thigh. The VenoValve is being evaluated in the surgical anti-reflux venous valve endoprosthesis (SAVVE) United States clinical trial. In addition to the VenoValve, the Company is focused on the development of a second device, enVVe, for the treatment of venous disease.

Closing Price
Day's Change
0.00 (0.00%)
B/A Size
Day's High
Day's Low

10-day average volume:

Wells Fargo outshines JPMorgan as big banks kick off the fourth-quarter earnings season

12:01 pm ET January 15, 2022 (MarketWatch)

By Steve Gelsi

JPMorgan shares fall, while Wells Fargo gains in Q4 tale of two banks

JPMorgan Chase & Co.'s shares wrapped up trading with their biggest one-day loss since April of 2020 in Friday's busy day of fourth-quarter bank earnings.

Wall Street investors punished shares of JPMorgan Chase (JPM) with a drop of 6.2% at the close of a bruising session. It's the stock's heftiest one-day slide since April 1, 2020, when it lost 6.3%. Meanwhile, Citigroup (C) dropped by 1.3% and Wells Fargo & Co. (WFC) bucked the trend by advancing 3.7%.

At the closing bell on Friday, JPMorgan shares erased their gains since the start of 2022 and dipped 0.3%. The stock is still up 12.5% in the past 12 months.

Including Friday's gains, Wells Fargo is up 21% since Jan. 1, while Citigroup has gained about 10.8% so far in 2022.

Wells Fargo's 2022 guidance also beat expectations, while JPMorgan's view fell short.

In 2022, Wells Fargo expects 8% growth over its $35.8 billion in net interest income or about $38.66 billion. That figure would beat the latest analyst consensus estimate of $37 billion in net interest income in 2022, according to a survey by FactSet.

Meanwhile, JPMorgan Chase (JPM) expects 2022 net interest income of about $50 billion, which is below the latest Wall Street target of $55.7 billion. JPMorgan Chase also expects about $77 billion in adjusted noninterest expense. Jefferies analyst Ken Usdin said the company's cost target came in about 6% above Wall Street estimates.

JPMorgan profit drops by nearly $2 billionJPMorgan Chase said its fourth-quarter net income fell to $10.4 billion, or $3.33 a share, from $12.14 billion, or $3.79 a share in the year-ago quarter. The results included the benefit of $1.8 billion, or 47 cents per share, from the release of credit reserves.

Managed revenue rose 1% to $30.3 billion, with reported revenue of $29.3 billion. The megabank was expected to earn $3.01 a share and generate revenue of $29.78 billion, according to FactSet.

Total markets revenue of $5.3 billion fell 11%, including a drop of 16% in fixed-income markets and a 2% dip in equity markets.

"The economy continues to do quite well despite headwinds related to the omicron variant, inflation and supply chain bottlenecks," Chief Executive Jamie Dimon said. "Credit continues to be healthy with exceptionally low net charge-offs, and we remain optimistic on U.S. economic growth as business sentiment is upbeat and consumers are benefiting from job and wage growth."

Drilling into the numbers, Jefferies analyst Ken Usdin said JPMorgan's managed revenue missed estimates on flat mortgage origination volumes.

The bank's 11% drop in trading revenue was close to the firm's previous estimate for a loss of 10%, Usdin said.

With brisk capital markets and M&A activity, the firm's investment banking fees rose 37% to $3.5 billion.

Usdin said JPMorgan's credit card fees -- up $100 million from the previous quarter -- amounted to "good news" and that credit card sales volumes rose 29% over the year-ago period.

Earlier this week, Ellen Hazen, portfolio manager at F.L.Putnam Investment Management, said JPMorgan remains one of the firm's core holdings due to its "very strong" position in investment banking, commercial, and consumer banking.

She said she's looking for more signs of loan growth, as well as plans by the bank to invest in technology to compete with fintech rivals.

"Management has already indicated that it is willing to use its strong balance sheet to invest in the business," Hazen told MarketWatch. "Right now, two areas stand out: compensation expenses and fintech investments. Note, the latter is likely to be a short-term pain, long-term gain investment. Competing with well-funded fintech companies will cost JPM in the short-term, but will allow it to continue its dominance among consumers in the long-term."

In terms of loan growth, JPMorgan revealed some positive numbers on Friday, with a rise of 18% driven by securities-based lending. Card loan growth increased by 5%.

Wells Fargo profit increases by $2.7 billionWells Fargo's fourth-quarter profit increased to $5.75 billion, or $1.38 a share, from $3.09 billion, or 66 cents a share in the year-ago quarter. Revenue increased to $20.86 billion from $18.49 billion.

The San Francisco-based banking giant was expected to earn $1.11 a share on revenue of $18.79 billion, according to a FactSet survey of Wall Street analysts. "The changes we've made to the company and continued strong economic growth prospects make us feel good about how we are positioned entering 2022," CEO Charlie Scharf said. "But we also remain cognizant that we still have a multiyear effort to satisfy our regulatory requirements -- with setbacks likely to continue along the way -- and we continue our work to put exposures related to our historical practices behind us."

See Also:Wells Fargo now sees regulatory issues as 'likely'

Scharf said the bank's lending activity gained momentum in the second half of 2021 with 5% growth in loans from its consumer and commercial portfolios during the latter half of the year.

"We continued to manage credit well and the strong economic environment helped reduce charge-offs to historical lows" Scharf added.

Citigroup earnings drop by about $1.1 billion

Citigroup reported fourth-quarter net income of $3.17 billion, or $1.46 a share, down from $4.3 billion, or $1.92 a share, in the year-ago period. Revenue increased to $17 billion from $16.8 billion.

The New York-based bank beat the Wall Street consensus of $1.39 in earnings on revenue of $16.85 billion. Citi said it faced higher expenses, partially offset by higher revenue and lower cost of credit.

The latest quarter also included a pre-tax impact of approximately $1.2 billion related to its previously announced divestiture of its consumer banking businesses in Asia.

Earlier on Friday, the bank said it agreed to sell its consumer banking franchises in Indonesia, Malaysia, Thailand, and Vietnam to United Overseas Bank Ltd. . The deal includes a premium of about $690 million paid to Citigroup; plus a payment for the net assets of the acquired businesses.

UOB disclosed $2.98 billion in aggregate net asset value for Citigroup's consumer business, which includes Citigroup's retail banking. The deal will affect about 5,000 of Citigroup's consumer bank and supporting employees who are targeted to transfer to UOB.

Earlier this week, Citigroup revealed plans to exit its consumer business in Mexico, but it has yet to name a buyer. The move took Wall Street analysts by surprise.

Also Read:JPMorgan, Goldman profit updates may shape bank stock rally

-Steve Gelsi


(END) Dow Jones Newswires

January 15, 2022 12:01 ET (17:01 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.